FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4383313661> ?p ?o ?g. }

• W4383313661 abstract "Introduction Autoimmune diseases have been linked to COVID-19 vaccines. An increasing number of cases have reported de novo immune thrombocytopenia (ITP) following mRNA COVID-19 vaccines. This study aims to investigate the incidence of de novo ITP following the mRNA COVID-19 vaccine in comparison to other non-mRNA vaccines and COVID-19. Methods Data were collected from the TriNetX global health research network, which covers over 117 million patients. Four different patient cohorts were included: those who received the mRNA COVID-19 vaccine (between 12/15/2020 - 5/1/2023), the influenza vaccine (between 01/01/2010 - 01/01/2020), tetanus, diphtheria, and pertussis/tetanus and diphtheria (Tdap/Td) vaccines (between 01/01/2010 - 01/01/2020), and those who had COVID-19 (between 01/01/2020 - 05/01/2023). A comparative analysis was conducted to examine the occurrence of de novo ITP within three weeks after receiving mRNA COVID-19 vaccine, non-mRNA vaccines, or upon diagnosis of COVID-19. Additionally, a comparative analysis was performed after 1:1 propensity score matching to balance baseline characteristics (age, sex, and race). Results The overall event rate was 0.07 per 10,000 for the mRNA COVID-19 vaccine, 0.25 per 10,000 for the influenza vaccine, and 0.28 per 10,000 for the Tdap/Td vaccines. Additionally, the incidence of de novo ITP following COVID-19 was 0.30 per 10,000. Those who received the influenza vaccine and Tdap/Td vaccines had higher rates of de novo ITP compared to the mRNA COVID-19 vaccine group, with a relative risk of 3.48 and 3.88, respectively. The occurrence of de novo ITP following COVID-19 was significantly higher compared to that following the mRNA COVID-19 vaccine, with a relative risk of 4.27. Post-propensity score matching analysis produced similar outcomes. Conclusions The findings of this study suggest that the incidence of de novo ITP is significantly lower following mRNA-based COVID-19 vaccines compared to non-mRNA vaccines and COVID-19." @default.
• W4383313661 created "2023-07-07" @default.
• W4383313661 creator A5082947489 @default.
• W4383313661 date "2023-07-06" @default.
• W4383313661 modified "2023-10-18" @default.
• W4383313661 title "Comparative Analysis of De Novo Immune Thrombocytopenia Following mRNA COVID-19 Vaccine Versus Non-mRNA Vaccines and COVID-19: A Global Database Analysis" @default.
• W4383313661 cites W2787483926 @default.
• W4383313661 cites W3028098130 @default.
• W4383313661 cites W3087313970 @default.
• W4383313661 cites W3111255098 @default.
• W4383313661 cites W3157637563 @default.
• W4383313661 cites W3167123164 @default.
• W4383313661 cites W4200092905 @default.
• W4383313661 cites W4205483821 @default.
• W4383313661 cites W4206305135 @default.
• W4383313661 cites W4229452462 @default.
• W4383313661 cites W4283163559 @default.
• W4383313661 cites W4288205422 @default.
• W4383313661 cites W4294921240 @default.
• W4383313661 cites W4307991374 @default.
• W4383313661 cites W4312129681 @default.
• W4383313661 cites W4313340034 @default.
• W4383313661 cites W4367553907 @default.
• W4383313661 doi "https://doi.org/10.7759/cureus.41460" @default.
• W4383313661 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37546093" @default.
• W4383313661 hasPublicationYear "2023" @default.
• W4383313661 type Work @default.
• W4383313661 citedByCount "0" @default.
• W4383313661 crossrefType "journal-article" @default.
• W4383313661 hasAuthorship W4383313661A5082947489 @default.
• W4383313661 hasBestOaLocation W43833136611 @default.
• W4383313661 hasConcept C126322002 @default.
• W4383313661 hasConcept C159047783 @default.
• W4383313661 hasConcept C203014093 @default.
• W4383313661 hasConcept C22070199 @default.
• W4383313661 hasConcept C2779134260 @default.
• W4383313661 hasConcept C2779841045 @default.
• W4383313661 hasConcept C2780572238 @default.
• W4383313661 hasConcept C2780689484 @default.
• W4383313661 hasConcept C3008058167 @default.
• W4383313661 hasConcept C524204448 @default.
• W4383313661 hasConcept C71924100 @default.
• W4383313661 hasConceptScore W4383313661C126322002 @default.
• W4383313661 hasConceptScore W4383313661C159047783 @default.
• W4383313661 hasConceptScore W4383313661C203014093 @default.
• W4383313661 hasConceptScore W4383313661C22070199 @default.
• W4383313661 hasConceptScore W4383313661C2779134260 @default.
• W4383313661 hasConceptScore W4383313661C2779841045 @default.
• W4383313661 hasConceptScore W4383313661C2780572238 @default.
• W4383313661 hasConceptScore W4383313661C2780689484 @default.
• W4383313661 hasConceptScore W4383313661C3008058167 @default.
• W4383313661 hasConceptScore W4383313661C524204448 @default.
• W4383313661 hasConceptScore W4383313661C71924100 @default.
• W4383313661 hasLocation W43833136611 @default.
• W4383313661 hasLocation W43833136612 @default.
• W4383313661 hasLocation W43833136613 @default.
• W4383313661 hasOpenAccess W4383313661 @default.
• W4383313661 hasPrimaryLocation W43833136611 @default.
• W4383313661 hasRelatedWork W2012925344 @default.
• W4383313661 hasRelatedWork W2028507949 @default.
• W4383313661 hasRelatedWork W2114347378 @default.
• W4383313661 hasRelatedWork W2327414618 @default.
• W4383313661 hasRelatedWork W2408362261 @default.
• W4383313661 hasRelatedWork W2439514741 @default.
• W4383313661 hasRelatedWork W2513868392 @default.
• W4383313661 hasRelatedWork W2808612967 @default.
• W4383313661 hasRelatedWork W4382631683 @default.
• W4383313661 hasRelatedWork W4383500879 @default.
• W4383313661 isParatext "false" @default.
• W4383313661 isRetracted "false" @default.
• W4383313661 workType "article" @default.